Archive

« Older Entries

TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform Monday, December 23rd, 2013
Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest an [...]
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study Tuesday, December 17th, 2013
Dose confirmed for Phase Ib safety and efficacy expansion study 17 December 2013 Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibod [...]
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan designation in chronic lymphocytic leukemia Monday, December 16th, 2013
Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, t [...]
Probiodrug Publishes Further Evidence Correlating Glutaminyl Cyclase (QC) with Alzheimer’s Disease Pathogenesis and Cognitive Decline Tuesday, December 3rd, 2013
HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researchers from the Paul Flechsig Institute for Brain Research, University of Leipzig, Germany published results in the Journal of Alzheimer’s Dis [...]
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B Monday, November 4th, 2013
Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development 4 November 2013 Breda, The Netherlands / Ghent [...]
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer Monday, November 4th, 2013
4 November 2013 Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties w [...]
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies Wednesday, October 23rd, 2013
- Invention provides unique technology base for therapeutic human bispecific antibodies - Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes Utrecht, The Netherlands, October [...]
Hybrigenics 2013 first-half results Update on the development of inecalcitol Tuesday, October 22nd, 2013
+9% growth of Hybrigenics’ operating revenues 60% biological response rate of chronic lymphocytic leukemia patients to oral inecalcitol US Patent protection for high dose inecalcitol until 2031 [...]
Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections Tuesday, October 22nd, 2013
New cartridge detects 114 targets Roll-out in collaboration with Heraeus Medical expected in early 2014 Holzgerlingen, Germany, October 22, 2013 -- Curetis AG today announced first details on its new Unyvero™ i60 [...]
Hybrigenics acquires the genomic activities of Imaxio Pradeyrol Development invests EUR 1.3 million in Hybrigenics Friday, October 11th, 2013
Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and speciali [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview

Archive

« Older Entries

TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform Monday, December 23rd, 2013
Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest an [...]
ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study Tuesday, December 17th, 2013
Dose confirmed for Phase Ib safety and efficacy expansion study 17 December 2013 Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibod [...]
Hybrigenics’ inecalcitol receives positive opinion from EMA for orphan designation in chronic lymphocytic leukemia Monday, December 16th, 2013
Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, t [...]
Probiodrug Publishes Further Evidence Correlating Glutaminyl Cyclase (QC) with Alzheimer’s Disease Pathogenesis and Cognitive Decline Tuesday, December 3rd, 2013
HALLE/SAALE, Germany--(BUSINESS WIRE)-- Probiodrug AG (Probiodrug) and researchers from the Paul Flechsig Institute for Brain Research, University of Leipzig, Germany published results in the Journal of Alzheimer’s Dis [...]
arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B Monday, November 4th, 2013
Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development 4 November 2013 Breda, The Netherlands / Ghent [...]
arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer Monday, November 4th, 2013
4 November 2013 Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties w [...]
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies Wednesday, October 23rd, 2013
- Invention provides unique technology base for therapeutic human bispecific antibodies - Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes Utrecht, The Netherlands, October [...]
Hybrigenics 2013 first-half results Update on the development of inecalcitol Tuesday, October 22nd, 2013
+9% growth of Hybrigenics’ operating revenues 60% biological response rate of chronic lymphocytic leukemia patients to oral inecalcitol US Patent protection for high dose inecalcitol until 2031 [...]
Curetis Presents First Data on Novel Unyvero™ i60 ITI Application for Implant and Tissue Infections Tuesday, October 22nd, 2013
New cartridge detects 114 targets Roll-out in collaboration with Heraeus Medical expected in early 2014 Holzgerlingen, Germany, October 22, 2013 -- Curetis AG today announced first details on its new Unyvero™ i60 [...]
Hybrigenics acquires the genomic activities of Imaxio Pradeyrol Development invests EUR 1.3 million in Hybrigenics Friday, October 11th, 2013
Paris, 11 October 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and speciali [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview